filmov
tv
Dose Modification Rationale in Advanced Pancreatic Cancer
Показать описание
The panelists, Philip A. Philip, MD, PhD, FRCP; Johanna Bendell, MD; Caio Rocha Lima, MD; Thomas A. Abrams MD; and George P. Kim, MD, deliberate dose modification practices with the pancreatic cancer chemotherapy regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel.
0:09:53
Dose Modification Rationale in Advanced Pancreatic Cancer
0:03:08
Cabozantinib Dose Modification
0:02:26
Dr. Mirza Discusses Niraparib Dose Modifications for Ovarian Cancer Patients With Low Body Weight
0:17:47
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on...
0:58:46
Kidney Function and Medication Dosing Adjustments in the Older Adult
0:02:16
Rationale for Combining a Modified IL-2 and Nivolumab in Melanoma
0:10:27
Multidisciplinary Care Model – Rationale and Approach for Building Your Team
0:53:33
Rational Design of Modified Release Dosage Forms
0:13:07
Multidisciplinary Care Model: Rationale for Building Your Team
0:00:20
1st yr. Vs Final yr. MBBS student 🔥🤯#shorts #neet
0:21:13
Biologic Rationale, Development History, and Practical Dosing and Administration
0:42:27
What you should know about FDA Project Optimus for your oncology drug approval
0:20:02
Management of Differentiated Thyroid Carcinoma in the Era of Targeted Therapy
0:01:00
Pro-Choicer Defeated By Simple Logic | Kristan Hawkins | UTSA
0:10:44
Another Reason Why Clinical Research Oncology Is Difficult: Dose Reductions and Adverse Events
0:01:09
Tracheostomy Care | Roswell Park Patient Education
0:22:22
Rational Modifications to CAR Antigen Binding Domain Improve Sensitivity to Low-Density Target...
0:29:17
Rationale for Dual Therapy with Therapies Targeting CGRP Signaling | Prof. Dodick | ICAMS 2022
0:52:31
Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care
0:00:54
Great Example of Hypergamy
0:04:15
THIS Destroys Spike Protein!?
0:58:11
Crafting the New Treatment Mix in CLL
0:47:11
Treatment rationale of CAD in Advanced CKD - Dr. Mirna mamdouh
0:11:11
Rationale for Selinexor Treatment in Daratumumab-Refractory Multiple Myeloma Patients
Комментарии